Cathie's Ark Logo
Exact Sciences Corp. Logo

ARKK Holdings of Exact Sciences Corp. (EXAS) - Updated Daily

Liquid BiopsyGenomicsGenetic Testing
Date
Direction
Shares
Fund Weight
Fund
June 2, 2023
SELL23.711k0.0255%ARKK
May 25, 2023
SELL158.542k0.1702%ARKK
May 24, 2023
SELL40.103k0.0433%ARKK
May 23, 2023
SELL102.986k0.1116%ARKK
May 18, 2023
SELL141.915k0.1557%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
5.09%$15.13b
🏋🏿‍♂️Weight Rank In ARKK🌏Country
7🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
6$106.19
🎫ARK Ownership Percent
2.63%
Description
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com
Website
exactsciences.com

Other ETFs That Hold EXAS

Ticker
NameWeight
ARKGARK Genomic Revolution ETF11.77%
ARKKARK Innovation ETF6.43%
XBISPDR® S&P Biotech ETF1.49%
AGNGGlobal X Aging Population ETF0.85%
LABUS&P Biotech Bull 3X Shares ETF0.209%

Research Notes and Commentary for EXAS

No Research Notes Found for EXAS